ABBV-CLS-579 + PD-1 inhibitor

ABBV-CLS-579 + PD-1 inhibitor is an investigational **combination therapy** being studied for the treatment of advanced or metastatic solid tumors, including head and neck squamous cell carcinoma, non-small cell lung cancer, microsatellite instability-high tumors, and clear cell renal cell carcinoma. **ABBV-CLS-579** is a selective, small molecule inhibitor of **protein tyrosine phosphatases PTPN2 and PTPN1**, which are involved in negative regulation of anti-tumor immune responses. The combination also includes a **PD-1 inhibitor** (such as pembrolizumab), a class of monoclonal antibodies that block the programmed cell death-1 (PD-1) immune checkpoint to enhance T-cell mediated anti-tumor activity. The combination aims to boost immune recognition and killing of tumor cells by simultaneously inhibiting PTPN2/PTPN1 and the PD-1 pathway. The main developers are **AbbVie** and **Calico Life Sciences**. ABBV-CLS-579 is administered orally, typically in combination with an intravenous PD-1 inhibitor. The combination is currently undergoing phase 1 clinical testing to evaluate safety, tolerability, and anti-tumor activity in patients with advanced or refractory cancers[1][3][4][7].